Market Overview:
The global primary progressive multiple sclerosis treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of primary progressive multiple sclerosis, rising awareness about available treatments, and growing investments by key players in research and development. Based on type, the global primary progressive multiple sclerosis treatment market is segmented into apomorphine (ApE), biotin, GZ-402668, ibudilast, idebenone, laquinimod sodium (LAQ), and others. Based on application, the market is segmented into hospitals, clinics,, and others. Geographically speaking,, North America dominates the global primary progressive MS treatment market followed by Europe,. Asia Pacific is projected to be fastest growing region over the forecast period owing to increasing prevalence of MS in countries such as China and India. Latin America holds a significant share of this market due to high prevalence rates for MS in countries such as Brazil.
Product Definition:
Primary Progressive Multiple Sclerosis Treatment is used to help people who have Primary Progressive Multiple Sclerosis. It is important to get treatment for Primary Progressive Multiple Sclerosis because it can help you stay healthy and feel better.
ApE:
Apeiron Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel interventional therapies for the treatment of primary progressive multiple sclerosis (PPMS). ApE’s lead product candidate, APD-991, is an investigational new drug developed to treat PPMS.
Biotin:
Biotin is a vitamin-like substance that functions as an internal combustion engine in the human body. Biotin helps in cell growth, healthy & proper functioning of cells, and also aids in the prevention of cell death. It also helps to improve mental health and promotes heart health by regulating blood sugar levels. Increasing cases of multiple sclerosis are expected to drive biotin demand over the forecast period.
Application Insights:
The others segment held the largest share of more than 60.0% in 2017. The application includes off-label uses such as rheumatoid arthritis, osteoarthritis, and other autoimmune conditions. Increasing awareness about PMS is one of the key factors driving this segment growth as patients seek alternative treatment options for their condition that have been proven to be safer and more effective than conventional ones.
PMT is expected to be the fastest growing application over the forecast period owing to increasing adoption of these drugs for treating relapsing remitting multiple sclerosis (RRMS). These drugs are also being studied for treating primary progressive MS (PPMS) due to their ability to reduce inflammation and halt disease progression in animal models affected with this condition.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some factors driving the growth of this regional market. In addition, launch of new products such as Erenumab-secreting Kineret in U.S., which is under FDA approval for treating PPMS symptoms is expected to boost revenue growth over the forecast period.
Asia Pacific region is anticipated to witness lucrative CAGR during the forecast period owing to rising disposable income leading to improved lifestyle among individuals triggering multiple sclerosis symptoms and other associated disorders such as optic neuritis and bladder obstruction among others (OAB). Moreover, growing awareness about available treatment options will drive demand further over the next eight years.
Growth Factors:
- Increasing incidence of primary progressive multiple sclerosis (PPMS)
- Growing awareness about PPMS and its treatment options
- Rising demand for better and more effective treatments for PPMS
- Availability of new and innovative therapies for PPMS
- Growing investment in research and development of new therapies for PPMS
Scope Of The Report
Report Attributes
Report Details
Report Title
Primary Progressive Multiple Sclerosis Treatment Market Research Report
By Type
ApE, Biotin, GZ-402668, Ibudilast, Idebenone, Laquinimod Sodium, Others
By Application
Hospital, Clinic, Others
By Companies
F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc., Kyorin Pharmaceutical Co., Ltd., MedDay SA, Santhera Pharmaceuticals Holding AG, Teva Pharmaceutical Industries Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
129
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Primary Progressive Multiple Sclerosis Treatment Market Report Segments:
The global Primary Progressive Multiple Sclerosis Treatment market is segmented on the basis of:
Types
ApE, Biotin, GZ-402668, Ibudilast, Idebenone, Laquinimod Sodium, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche Ltd.
- Genzyme Corporation
- Glialogix, Inc.
- Kyorin Pharmaceutical Co., Ltd.
- MedDay SA
- Santhera Pharmaceuticals Holding AG
- Teva Pharmaceutical Industries Ltd.
Highlights of The Primary Progressive Multiple Sclerosis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ApE
- Biotin
- GZ-402668
- Ibudilast
- Idebenone
- Laquinimod Sodium
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Primary Progressive Multiple Sclerosis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Primary progressive multiple sclerosis (PPMS) is a chronic, disabling disease that attacks the central nervous system. PPMS is characterized by an initial period of relative stability, followed by a gradual decline in function over time. The cause of PPMS is unknown but may involve genetic and environmental factors. Treatment typically includes medications to control symptoms and rehabilitation to help people maintain their independence. There is no cure for PPMS, but treatments can improve people's quality of life.
Some of the major companies in the primary progressive multiple sclerosis treatment market are F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc., Kyorin Pharmaceutical Co., Ltd., MedDay SA, Santhera Pharmaceuticals Holding AG, Teva Pharmaceutical Industries Ltd..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Primary Progressive Multiple Sclerosis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Primary Progressive Multiple Sclerosis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Primary Progressive Multiple Sclerosis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Primary Progressive Multiple Sclerosis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Primary Progressive Multiple Sclerosis Treatment Market Size & Forecast, 2020-2028
4.5.1 Primary Progressive Multiple Sclerosis Treatment Market Size and Y-o-Y Growth
4.5.2 Primary Progressive Multiple Sclerosis Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ApE
5.2.2 Biotin
5.2.3 GZ-402668
5.2.4 Ibudilast
5.2.5 Idebenone
5.2.6 Laquinimod Sodium
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Primary Progressive Multiple Sclerosis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ApE
9.6.2 Biotin
9.6.3 GZ-402668
9.6.4 Ibudilast
9.6.5 Idebenone
9.6.6 Laquinimod Sodium
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ApE
10.6.2 Biotin
10.6.3 GZ-402668
10.6.4 Ibudilast
10.6.5 Idebenone
10.6.6 Laquinimod Sodium
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ApE
11.6.2 Biotin
11.6.3 GZ-402668
11.6.4 Ibudilast
11.6.5 Idebenone
11.6.6 Laquinimod Sodium
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ApE
12.6.2 Biotin
12.6.3 GZ-402668
12.6.4 Ibudilast
12.6.5 Idebenone
12.6.6 Laquinimod Sodium
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ApE
13.6.2 Biotin
13.6.3 GZ-402668
13.6.4 Ibudilast
13.6.5 Idebenone
13.6.6 Laquinimod Sodium
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Primary Progressive Multiple Sclerosis Treatment Market: Competitive Dashboard
14.2 Global Primary Progressive Multiple Sclerosis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 F. Hoffmann-La Roche Ltd.
14.3.2 Genzyme Corporation
14.3.3 Glialogix, Inc.
14.3.4 Kyorin Pharmaceutical Co., Ltd.
14.3.5 MedDay SA
14.3.6 Santhera Pharmaceuticals Holding AG
14.3.7 Teva Pharmaceutical Industries Ltd.
